Current Partnership
Simcere has started actively exploring opportunities to source global innovations through different collaboration models since 2006. We believe that we can maximize the value of the partnered products and bring additional value to our partner by leveraging our homeland advantages, experienced R&D team and powerful commercial platform.
Current Partnership
Jan. 08, 2018, Merus and Simcere Pharmaceutical Group announced that Merus has agreed to grant Simcere an exclusive license to develop and commercialize in China three bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform in the area of immuno-oncology. Merus will retain all rights outside of China.
On September 26, 2017, Amgen and Simcere announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology. Under the terms of the agreement, Amgen will remain responsible for the co-development, marketing approval applications and manufacturing of the biosimilars. Simcere will be responsible for distribution and commercialization in China, while Amgen will have a limited right to co-promote the products. The biosimilars included in the agreement are a part of Amgen's existing biosimilars portfolio.
Celon Pharma
On December 5, 2015, Simcere and Celon Pharma established the partnership to develop high quality pharmaceutical products in China. Celon Pharma S.A. is an integrated pharmaceutical company in Europe which focuses on advanced pharmaceutical research and manufacture.
Daiichi Sankyo
On December 5, 2015, Simcere and Daiichi Sankyo entered into a long-term strategic partnership in China. Simcere will have an exclusive right to promote and distribute Olmetec Plus ® in China. Olmetec Plus ®, an anti-hypertension oral combination of olmesartan medoxomil and hydrochlorothiazide, was developed by Daiichi Sankyo and launched in China in 2012.
Bristol-Myers Squibb (BMS), US
On November 3, 2010, Simcere and BMS established a strategic partnership to research and develop BMS-817378 for the potential treatment of tumors. Simcere receives exclusive right to develop and commercialize BMS-817378 in China while Bristol-Myers Squibb retains exclusive rights in all other markets. This unique arrangement represents a creative approach to accelerate a preclinical oncology compound to clinical proof-of-concept by leveraging the complementary strengths of a premier Chinese pharmaceutical company and a global pharmaceutical company. This partnership also represents a novel model for Sino-US cooperation. June 14, 2013, Simcere and BMS expanded their strategic relationship to co-develop and co-commercialize Orencia ® SC (abatacept) in China. Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan. Simcere will perform and fund all development and regulatory activities required to obtain market approval for Orencia SC in China. The companies will share responsibility for commercializing Orencia and related profits and losses. BMS is a top-ten global biopharmaceutical company with a long and successful history. With its 54,000 employees in 120 countries, BMS is a diversified and R&D-oriented enterprise with annual sales of $15 billion.
Epitomics/Apexigen, US
In 2008, Simcere and Epitomics entered into a strategic partnership to jointly develop novel humanized rabbit anti-VEGF monoclonal antibody (SIM-BD0801). Under this agreement, Simcere owns 100% of the China right, and 50% of ex-China right.
Advenchen Laboratory, US
In 2007, Simcere and Advenchen Laboratory entered into a joint research agreement on anti-tumor drug AL6802.
Pharmaceutical Companies
Healthcare Dedicated Fund
© Copyright 2016 www. All Rights Reserved.